ReviewHistopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature
Introduction
Antiphospholipid antibodies (aPLs) are a heterogeneous group of autoantibodies that are found in 0–5% of the general population [1], [2] and in up to 40% of women suffering from stillbirth and/or recurrent miscarriage [3], [4], [5], [6], [7]. Antiphospholipid antibodies are also significantly associated with preeclampsia, intrauterine growth restriction and premature birth [4], [7], [8], [9], [10] as well as arterial and venous thrombosis [11], [12], [13], [14]. Antiphospholipid antibodies react with a complex antigen involving anionic phospholipids and phospholipid-binding proteins, such as β2 glycoprotein I. More than 18 aPLs have been reported, although only anti-β2 glycoprotein I antibodies, anticardiolipin antibodies, and the lupus anticoagulant are considered clinically relevant in most individuals. Women who experience arterial/venous thrombosis and/or obstetric morbidity and test positive for one or more of the clinically relevant aPLs are defined as having the antiphospholipid antibody syndrome (APS) [15].
Obstetric morbidity in women with the APS may be due to the detrimental effects of aPLs on the placenta, an organ whose function is critical to the success of pregnancy. The human placenta consists of an extensive network of finger-like projections, or placental villi, most of which float in the maternal blood-filled intervillous space. All floating placental villi are covered by a multinucleated cell called the syncytiotrophoblast. The syncytiotrophoblast is a sessile, terminally differentiated epithelium that is maintained by the continuous incorporation of nuclei and cellular machinery from underlying villous cytotrophoblasts. Villous cytotrophoblasts proliferate and then fuse with the syncytiotrophoblast in a process called syncytialisation. Three to four weeks following syncytialisation [16], syncytiotrophoblast nuclei cluster, become increasingly heterochromatic and undergo DNA fragmentation [17], [18]. Histologically, clusters of heterochromatic syncytiotrophoblast nuclei are called syncytial knots [19]. Syncytial knots and smaller fragments of the syncytiotrophoblast (collectively termed trophoblast debris) may be extruded from the surface of the syncytiotrophoblast into the maternal blood [20], [21] in a process akin to the apoptotic blebbing of mononuclear cells [22]. Beneath the syncytiotrophoblast and villous cytotrophoblasts is the stromal core of the placental villus, which contains foetal blood vessels, fibroblasts and macrophages.
In some placental villi, specialised populations of villous cytotrophoblasts give rise to extravillous trophoblasts, which penetrate through the syncytiotrophoblast and grow into the maternal decidua, thereby anchoring the placenta to the uterus [19]. Extravillous trophoblasts also invade the uterine spiral arteries, initially forming plugs that partially or fully occlude the lumens of spiral arteries [23], and later transforming the spiral arteries into large-bore, non-vasoactive vessels that maximize maternal blood supply to the placenta [19].
In vitro work has demonstrated that aPLs adversely affect trophoblast function [24]. Specifically, treatment of trophoblasts or placental villous explants with aPLs has been shown to decrease trophoblast proliferation [25], syncytialisation [26], [27], and invasion [27], [28], [29], [30], [31], [32], [33]. Antiphospholipid antibodies also appear to affect trophoblast death [24], as treatment of placental explants with aPLs increases trophoblast apoptosis [34], [35], [36] and the release of trophoblast debris from the syncytiotrophoblast [37].
In addition to affecting trophoblast function and death, aPLs may also contribute to placental dysfunction and thus, obstetric morbidity by triggering thrombosis in the intervillous space. Placental thrombosis is conceivable given that aPLs promote thrombosis in the systemic circulation [11], [12], [13], [14], and since the intervillous space is a site of blood turbulence and blood stasis. Moreover, the syncytiotrophoblast naturally exteriorises phosphatidylserine [38], [39], [40], a trigger of contact-dependent coagulation [41]. In normal pregnancies, exteriorised phosphatidylserine may be protected from maternal coagulation factors by annexin V, a phosphatidylserine-binding protein [42] that is thought to form a lattice-like shield over the surface of the syncytiotrophoblast [43]. The annexin V shield may be disrupted in pregnancies affected by aPLs, as suggested by experiments performed in vitro, which have demonstrated that aPLs displace annexin V from the surface of placental explants [44], [45] or syncytialised trophoblasts [46], [47], [48], [49]. Following disruption of the annexin V shield, syncytialised trophoblasts bound more prothrombin [48] and more rapidly formed clots in cell-surface plasma coagulation assays [46], [47], suggesting that the changes in trophoblastic annexin V had pro-thrombotic consequences in vitro. Excessive coagulation on the surface of the syncytiotrophoblast may manifest as the deposition of fibrin around placental villi (perivillous fibrin deposition), or the formation of thrombi in the intervillous space. Both lesions have the capacity to obliterate the intervillous space, and may therefore render placental villous tissue ischaemic and functionally void [23].
Placental dysfunction and foetal demise in pregnancies complicated by aPLs may also reflect excessive inflammation within the uteroplacental site. The inflammatory insult may be driven by the activation of complement, as demonstrated by a series of elegant studies where pregnant mice were passively immunised with IgG from individuals with the APS [50]. Following the passive immunisation of pregnant mice, aPLs are thought to deposit within the uteroplacental site where they activate the classical complement cascade [51]. Activation of the classical complement cascade results in cleavage of complement component C3 into C3b, which is deposited on the surface of decidual cells [50]. Membrane-bound C3b then cleaves complement component C5 into C5a, an anaphylatoxin that promotes neutrophil activation and migration [51], that increases the expression of tissue factor and leads to neutrophil oxidative burst [52]. The reactive oxygen species, proteolytic enzymes and other inflammatory mediators released by neutrophils inflict damage within the uteroplacental site and lead to foetal demise in this mouse model of human APS pregnancy.
Antiphospholipid antibodies may also elicit a complement-independent inflammatory response in the uteroplacental site by signalling through Toll-like receptor 4 (TLR4) on extravillous trophoblasts [53]. Activation of TLR4 by aPLs results in the secretion of pro-inflammatory chemokines growth-related oncogene α and interleukin-8, as well as the potent pro-inflammatory cytokine interleukin-1β [53]. The conditioned media from extravillous trophoblasts treated with aPLs induces apoptosis in untreated extravillous trophoblasts, suggesting that the pro-inflammatory mediators produced in response to TLR4 activation may act in an autocrine or paracrine fashion to cause extravillous trophoblast death in vitro [53]. Failure of extravillous trophoblasts to invade and remodel the uterine spiral arteries could result in reduced placental blood supply and thus pregnancy morbidity.
In addition to the experiments performed in vitro or with mouse models, workers have also attempted to understand the underlying cause of obstetric morbidity in aPL-positive women by investigating the histopathology of placentae from these women. De Wolf and colleagues were the first to publish a histological report of a placenta from a pregnancy affected by aPLs. Fifty percent of the placenta in that report was infarcted, and several spiral arteries supplying the placenta with maternal blood were occluded by intraluminal thromboses [54]. The observation of spiral artery thrombosis and placental infarction in this and other early case reports [55], [56] was the impetus for the theory that thrombotic occlusion of the spiral arteries, impairment of placental blood supply, placental infarction, and a consequent reduction in materno-foetal exchange, was the cause of foetal demise in pregnancies affected by aPL. Since these initial case reports, many more workers have investigated the histopathology of placentae from aPL-positive women in larger case-control studies. However, not all of the placentae from aPL-positive women in these larger studies exhibited signs of spiral artery thrombosis or placental infarction, suggesting that the early theory implicating these lesions in foetal demise was overly simplistic and that other pathological processes may contribute to pregnancy morbidity in women with aPLs.
The prevalence of various histopathological lesions in the placentae of women with aPL has been difficult to reconcile from the existing literature since different case–control studies have investigated different histopathological lesions in several diverse groups of women with results that are often contradictory. This systematic review was undertaken in order to generate a complete and coherent picture of the placental features associated with aPLs in an attempt to better understand the underlying pathological processes that take place in aPL-affected pregnancies. It was hypothesised that, in line with the current evidence from in vitro work and mouse models, this would uncover a placental aPL fingerprint that involved thrombotic or inflammatory lesions or evidence of trophoblast dysfunction and death.
Section snippets
Search strategy
A systematic search of the literature was performed to identify all of the studies investigating the features of placentae from pregnancies complicated by aPLs. Maximal coverage was ensured by searching four databases: PubMed, Embase, Scopus and Web of Science. Records were retrieved on the 27th of November 2014 using the broad search strategy (“placenta” OR “trophoblast”) AND (“antiphospholipid antibody” OR “antiphospholipid syndrome”). Filters for English language and document type (journal
Search results
One thousand, one hundred and twelve records were retrieved from Pubmed (300), Embase (205), Scopus (300), and Web of Science (307). Seven additional records were sourced from searching the reference lists of relevant full-text articles. Duplicate records were removed and the titles and abstracts of 548 unique records were reviewed. Records were excluded because they were not relevant (411), they did not present primary data (25), they reported solely on the in vitro effects of aPLs on
Discussion
Since the report of De Wolf and colleagues in 1982 and the proposal that spiral artery thrombosis and placental infarction were the cause of aPL-related foetal demise, there have been several advances in our understanding of the mechanisms of action of aPLs. These insights have lead to the proposal that aPL-related obstetric morbidity may be due to trophoblast dysfunction/death, thrombosis in the intervillous space, or excessive inflammation in the uteroplacental site. However, these mechanisms
Funding
CAV is a recipient of a University of Auckland Doctoral Scholarship.
Disclosure statement
None to declare.
Take-home messages
- •
Antiphospholipid antibodies are associated with obstetric morbidity, but the cause of this association is not yet completely understood.
- •
In addition to experimental work performed in vitro or with mouse models, workers have attempted to understand the role of aPLs in obstetric morbidity by investigating the histopathology of placentae from aPL-positive women.
- •
This systematic review has collated data from 34 studies reporting on aPL-associated placental histopathology and has found that placental
References (116)
- et al.
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population
Am J Obstet Gynecol
(1989) - et al.
Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy
Obstet Gynecol
(1995) - et al.
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
Lancet
(1983) - et al.
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis
Autoimmun Rev
(2014) - et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
J Thromb Haemost
(2006) - et al.
Proliferation, differentiation and apoptosis in villous trophoblast at 13–41 weeks of gestation (including observations on annulate lamellae and nuclear pore complexes)
Placenta
(1999) - et al.
Trophoblast deportation part I: review of the evidence demonstrating trophoblast shedding and deportation during human pregnancy
Placenta
(2011) - et al.
Trophoblast deportation part II: a review of the maternal consequences of trophoblast deportation
Placenta
(2011) - et al.
Apoptosis and its role in the trophoblast
Am J Obstet Gynecol
(2006) - et al.
Action of anticardiolipin and antibodies to [beta]2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death
Lancet
(1998)
Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo)
Acta Histochem
Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro
Am J Obstet Gynecol
Anti-phospholipid antibodies increase non-apoptotic trophoblast shedding: a contribution to the pathogenesis of pre-eclampsia in affected women?
Placenta
Determination of non-bilayer phospholipid arrangements and their antibodies in placentae and sera of patients with hypertensive disorders of pregnancy
Placenta
Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts
Am J Obstet Gynecol
Monoclonal antiphospholipid antibody reactivity against human placental trophoblast
J Reprod Immunol
Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family
J Biol Chem
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay
Am J Pathol
Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi
Am J Obstet Gynecol
Reduction of annexin-V (placental anticoagulant protein-I) on placental v ll of women with antiphospholipid antibodies and recurrent-spontaneous abortion
Am J Obstet Gynecol
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
Blood
Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation
Am J Obstet Gynecol
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury
Blood
Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
Am J Obstet Gynecol
Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes
Placenta
Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death
Am J Obstet Gynecol
Placental pathology in systemic lupus erythematosus: a prospective study
Am J Obstet Gynecol
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies
Eur J Obstet Gynecol Reprod Biol
The placental bed in pregnancies complicated by primary antiphospholipid syndrome
Placenta
Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients
Obstet Gynecol
Normal expression of cell adhesion molecules in placentae from women with systemic lupus erythematosus and the antiphospholipid syndrome
Placenta
Cytotoxic antibody against trophoblast and lymphocytes present in pregnancy with intra-uterine fetal growth retardation and its relation to anti-phospholipid antibody
J Reprod Immunol
Pros and cons for C4d as a biomarker
Kidney Int
Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome
Am J Obstet Gynecol
Serial measurements of a plasma prostacyclin inhibitor in a patient with recurrent abortions and lupus anticoagulant; a case report
Eur J Obstet Gynecol Reprod Biol
Evidence for heterogeneity of the obstetric antiphospholipid syndrome: thrombosis can be critical for antiphospholipid-induced pregnancy loss
J Thromb Haemost
Maternal circulation in the first-trimester human placenta—myth or reality?
Am J Obstet Gynecol
Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome: a case report and review of the literature
Hum Pathol
Haemostatic mechanisms in human placenta
Best Pract Res Clin Haematol
Immunohistochemical distribution of Toll-like receptor 4 in term and preterm human placentas from normal and complicated pregnancy including chorioamnionitis
Hum Pathol
Antiphospholipid (Hughes) syndrome: an overview
Antiphospholipid antibodies in pregnancy: prevalence and clinical associations
Br J Obstet Gynaecol
Antiphospholipid antibodies in pregnancy
Aust N Z J Obstet Gynaecol
Epidemiology of antiphospholipid antibody syndrome
High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies
Hum Reprod
Antiphospholipid antibodies in patients with preeclampsia
Am J Reprod Immunol
The association of antiphospholipid antibodies with severe preeclampsia
Obstet Gynecol
beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women
Hum Reprod
Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test
Arch Intern Med
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
Lupus
Cited by (124)
The pathogenesis of obstetric APS: a 2023 update
2023, Clinical ImmunologyRenal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy
2022, Journal of AutoimmunityRecurrent miscarriage and low-titer antiphospholipid antibodies
2024, Clinical Rheumatology